| Financial Information Relating to Reportable Segments |
Following is financial
information relating to the Company’s reportable segments (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Quarter
Ended |
|
|
Six Months
Ended |
|
| |
|
December 31, |
|
|
December 31, |
|
| |
|
2012 |
|
|
2011 |
|
|
2012 |
|
|
2011 |
|
|
External sales
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
69,628 |
|
|
$ |
69,808 |
|
|
$ |
139,131 |
|
|
$ |
142,111 |
|
|
Hematology
|
|
|
5,455 |
|
|
|
4,854 |
|
|
|
10,977 |
|
|
|
10,147 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated net
sales
|
|
$ |
75,083 |
|
|
$ |
74,662 |
|
|
$ |
150,108 |
|
|
$ |
152,258 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings before income
taxes
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Biotechnology
|
|
$ |
36,883 |
|
|
$ |
37,878 |
|
|
$ |
73,877 |
|
|
$ |
77,862 |
|
|
Hematology
|
|
|
2,148 |
|
|
|
1,681 |
|
|
|
4,251 |
|
|
|
3,599 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment earnings before
income taxes
|
|
|
39,031 |
|
|
|
39,559 |
|
|
|
78,128 |
|
|
|
81,461 |
|
|
Unallocated corporate
expenses and equity method investee losses
|
|
|
(1,585 |
) |
|
|
(1,686 |
) |
|
|
(2,696 |
) |
|
|
(3,088 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated earnings
before income taxes
|
|
$ |
37,446 |
|
|
$ |
37,873 |
|
|
$ |
75,432 |
|
|
$ |
78,373 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|